ClinicalTrials.gg
CompletedNCT03745287Updated Sep 16, 2026Results posted

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

A Phase 2/3 interventional study of Exa-cel in Sickle Cell Disease, Hematological Diseases and Hemoglobinopathies, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 17 sites in 7 countries. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
157th of 559
63 · median 31
Started
2018
with 51 others
Phase 2/3
7 of 733
1 open now
Registered
435th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 157th largest by enrollment of the 559 interventional ones that give a count, is one of 52 that started in 2018, is one of 7 in phase 2/3, and was the 435th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participants with severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.

03

Conditions studied

  • Sickle Cell Disease
  • Hematological Diseases
  • Hemoglobinopathies
04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of severe sickle cell disease as defined by:
  • Documented severe sickle cell disease genotype
  • History of at least two severe vaso-occlusive crisis events per year for the previous two years prior to enrollment
  • Eligible for stem cell transplant as per investigators judgment

Key Exclusion Criteria:

  • An available 10/10 human leukocyte antigen (HLA)-matched related donor
  • Prior hematopoietic stem cell transplant (HSCT)
  • and active bacterial, viral, fungal, or parasitic infection

Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Exa-cel

    Exa-cel (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants received a single infusion of exa-cel through a central venous catheter on Day 1.

    Biological: Exa-cel

Interventions

  • BiologicalExa-cel

    Administered by IV infusion following myeloablative conditioning with busulfan.

    Also known as: Exagamglogene autotemcel, CTX001

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel Infusion

    A VOC is a condition of SCD characterized by vaso-occlusion presenting as recurrent pain episodes. The percentage of participants who remain VOC free after achieving VF12 were data reported in the outcome measure.

    Time frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

  2. Percentage of Participants Who Achieve Neutrophil Engraftment

    Neutrophil engraftment is defined as the first day of 3 consecutive measurements of absolute neutrophil count (ANC)≥500/μL on 3 different days, within 42 days after exa-cel infusion without the use of unmodified CD34+ cells after reaching the nadir, defined as ANC \<500/µL.

    Time frame: Up to 24 months post exa-cel infusion.

  3. Time to Neutrophil Engraftment for Participants Who Achieve Neutrophil Engraftment

    Neutrophil engraftment is defined as the first day of 3 consecutive measurements of absolute neutrophil count (ANC)≥500/μL on 3 different days, without use of the unmodified CD34+ cells after reaching the nadir, defined as ANC\<500/μL. Time to neutrophil engraftment was calculated by the neutrophil engraftment date subtract exa-cel infusion date +1.

    Time frame: Up to 24 months post exa-cel infusion.

  4. Time to Platelet Engraftment for Participants Who Achieve Platelet Engraftment

    Platelet engraftment is defined as the first day of 3 consecutive measurements of unsupported (no platelet transfusions for the last 7 days) platelet ≥50,000/μL on 3 different days after Exa-cel infusion. For participants discharged early day 7 after the last platelet transfusion will be the day of platelet engraftment, as long as 3 subsequent and consecutive unsupported measurements on 3 different days are \>50,000/μL. For participants who have been discharged prior to platelet engraftment, it is recommended to collect blood every 2 to 3 days to obtain an accurate assessment of platelet engraftment. Time to platelet engraftment was defined as first of 3 consecutive measurements on 3 different days with platelet ≥50 × 109/L without a platelet transfusion for 7 consecutive days.

    Time frame: From Exa-cel infusion up to 2 years after exa-cel infusion

  5. Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From receiving exa-cel infusion up to 2 years

  6. Transplant-related Mortality (TRM) Within 100 Days After Exa-cel Infusion

    The transplant-related mortality is defined as death related to Busulfan and/or exa-cel infusion. The number and proportion of TRM participants who have died within 100 days, or with at least 100 days post exa-cel infusion.

    Time frame: Within 100 days after exa-cel infusion

  7. Transplant-related Mortality Within 12 Months Post Exa-cel Infusion

    The transplant-related mortality is defined as death related to Busulfan and/or exa-cel infusion. The number and proportion of TRM within 12 months will be summarized for participants who have died within 12 months, or with at least 12 months post exa-cel infusion.

    Time frame: Within 12 months post exa-cel infusion

  8. All-cause Mortality

    All-cause mortality from exa-cel infusion up to 2 years

    Time frame: From exa-cel infusion up to 2 years

Secondary outcomes

  1. Percentage of Participants Free From Inpatient Hospitalization for Severe VOCs Sustained for at Least 12 Months (HF12)

    The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion.

    Time frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

  2. Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion

    The VF12 defines absence of any severe vaso-occlusive crises (VOCs) for at least 12 consecutive months after exa-cel infusion. Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs were included in the analysis. Relative reduction from baseline was calculated as 100 % × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years.

    Time frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

  3. Percentage of Participants With at Least 90% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion

    Percentage of participants with at least 90% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.

    Time frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

  4. Percentage of Participants With at Least 80% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion

    Percentage of participants with at least 80% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.

    Time frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

  5. Percentage of Participants With at Least 75% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion

    Percentage of participants with at least 75% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.

    Time frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

  6. Percentage of Participants With at Least 50% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion

    Percentage of participants with at least 50% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.

    Time frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

  7. Duration of Severe VOC Free in Participant Who Have Achieved VF12

    The VF12 means the absence of any severe VOC for at least 12 consecutive months after exa-cel infusion. The evaluation of the severe VOC free duration in participants who achieved VF12 started 60 days after the last RBC transfusion for post transplant support or SCD management.

    Time frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

  8. Relative Reduction From Baseline in Annualized Rate of Inpatient Hospitalizations for Severe VOCs Up to 24 Months After Exa-cel Infusion

    The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion. Relative reduction from baseline is calculated as 100% × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years. Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs are included in the analysis.

    Time frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

  9. Relative Reduction From Baseline in Annualized Duration of Hospitalization for Severe VOCs Who Did Not Achieve HF12 Up to 24 Months After Exa-cel Infusion

    The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion. Relative reduction from baseline is calculated as 100% × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years. Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs are included in the analysis.

    Time frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

  10. Percentage of Participants With Sustained Fetal Hemoglobin (HbF) Greater Than or Equal to (≥) 20% for at Least 3 Months

    The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.

    Time frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

  11. Percentage of Participants With Sustained HbF ≥ 20% for at Least 6 Months

    The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.

    Time frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

  12. Percentage of Participants With Sustained HbF ≥20% for at Least 12 Months

    The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.

    Time frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

  13. Number of Annualized Red Blood Cells (RBC) Units Transfused After Exa-cel Infusion

    The evaluation of the number of annualized RBC units transfused after exa-cel infusion started 12 months after exa-cel infusion.

    Time frame: 2 years after exa-cel infusion

  14. Participants With Relative Reduction From Baseline in Number of Annualized Units of Red Blood Cells Transfused

    Relative reduction from baseline = 100% × (Baseline value - post baseline value)/Baseline value. The evaluation of the number of annualized RBC units transfused after exa-cel infusion started 12 months after exa-cel infusion.

    Time frame: 2 years after exa-cel infusion

  15. Total Fetal Hemoglobin (HbF) Concentration Over Time

    Time frame: 2 years after exa-cel infusion

  16. Total Hemoglobin (Hb) Concentration Over Time

    Time frame: 2 years after exa-cel infusion

  17. Change From Baseline in Reticulocyte Count Over Time

    Time frame: 2 years after exa-cel infusion

  18. Change From Baseline in Indirect Bilirubin Over Time

    Time frame: 2 years after exa-cel infusion

  19. Percentage of Participants With Detectable Haptoglobin Over Time

    Time frame: 2 years after exa-cel infusion

  20. Percentage of Participants With Lactate Dehydrogenase (LDH) Level <300 Units Per Liter (U/L) Over Time

    Time frame: 2 years after exa-cel infusion

  21. Percentage of Alleles With Intended Genetic Modification Present in Peripheral Blood Leukocytes Over Time

    Time frame: 2 years after exa-cel infusion

  22. Percentage of Alleles With Intended Genetic Modification Present in CD34+ Cells of Bone Marrow Over Time

    Time frame: 2 years after exa-cel infusion

  23. Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥12 and <18 Years of Age

    The 11-point pain numerical rating scale (NRS) is used to measures pain intensity on a 1-dimensional score ranging from 0 (no pain) to 10 (worst possible pain).

    Time frame: 2 years after exa-cel infusion

  24. Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥18 and ≤35 Years of Age

    The 11 point pain numerical rating scale (NRS) is used to measures pain intensity on a 1 dimensional score ranging from 0 (no pain) to 10 (worst possible pain).

    Time frame: 2 years after exa-cel infusion

  25. Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-Y)Visual Analogue Scale (VAS) for Participants ≥12 and <18 Years of Age

    The EQ-5D VAS is a version of the EQ-5D designed for children and adolescents S). The EQ VAS records the subject's self-rated health on a 100-point VAS scale that ranged from 0 (worst imaginable health) to 100 (best imaginable health) points.

    Time frame: 2 years after exa-cel infusion

  26. Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-5L) for Participants ≥18 and ≤35 Years of Age

    The EQ-5D VAS is a version of the EQ-5D designed for children and adolescents S). The EQ VAS records the subject's self-rated health on a 100-point VAS scale that ranged from 0 (worst imaginable health) to 100 (best imaginable health) points.

    Time frame: 2 years after exa-cel infusion

  27. Change in PRO Over Time Assessed Using Functional Assessment of Cancer Therapy-bone Marrow Transplant (FACT-BMT) Score for Participants ≥18 and ≤35 Years of Age

    The Functional Assessment of Cancer Therapy-Bone Marrow Transplant scale (FACT-BMT) is a quality of life instrument that assesses the effects of bone marrow transplantation (BMT) on a patient's physical, social/family, emotional, and functional well-being while taking into consideration BMT-specific concerns. The assessment has different questions, each scored on a Likert scale from 0-4. The overall score is computed by adding scores of the questions and falls in the range 0-148, with higher scores indicating higher levels of overall well-being.

    Time frame: 2 years after exa-cel infusion

  28. Change in PRO Over Time Assessed Using Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Score on Different Domains for Participants ≥18 and ≤35 Years of Age

    ASCQ-Me is a disease-specific HRQoL questionnaire for adults with sickle cell disease that assesses Emotional Impact, Pain Impact, Social Functioning Impact, Stiffness Impact, Sleep Impact, Pain Episode Frequency, and Pain Episode Severity. Domain scores are reported as T-scores standardized to a reference population where mean = 50, and SD = 10. A change of approximately 5 points (1/2 SD) is considered clinically meaningful. An increase of 5 points indicates improvement for the impact domains, whereas a decrease of 5 points indicates improvement for the Pain Episode Frequency and Pain Episode Severity domains. For impact domain items higher score indicates better HRQoL and lower disease burden. For Pain items lower score indicates a better outcome. Scores are interpreted relative to the reference population mean of 50, taking into account the direction of scoring for each domain.

    Time frame: 2 years after exa-cel infusion

  29. Change in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age

    PedsQL scores were used to assess quality of life of participants. It is a standardized, generic instrument for measuring health related quality of life (HRQoL) in children and adolescents. It includes different domains (Psychosocial health, physical functioning, emotional functioning, social functioning, and school functioning). When completing the PedsQL questionnaires, respondents were asked to provide a response on a 5-point scale ranging from 0 (never a problem) to 4 (almost always a problem). Responses were then transformed to a 0 to 100 score, with higher scores reflecting better quality of life.

    Time frame: 2 years after Exa-cel infusion

  30. Change in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module (SCD) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age

    The PedsQL Sickle Cell Disease Module (PedsQL SCD) is a disease-specific module of the PedsQL. The tool measures self-reported health-related quality of life in participants with SCD across 9 domains: pain and hurt, pain impact, pain management (mgmt), worry I, worry II, emotions, treatment, communication I, and communication II. When completing the PedsQL SCD Module questionnaires, respondents were asked to provide a response on a 5-point scale ranging from 0 (never a problem) to 4 (almost always a problem). Responses were then transformed to a 0 to 100 score, with higher scores reflecting better quality of life.

    Time frame: 2 years after exa-cel infusion

07

Results

Posted Sep 16, 2026

Participant flow

Participant flow — Overall Study
MilestoneExa-cel (Exagamglogene Autotemcel)
Started63
Started mobilization58
Full analysis set46
Completed45
Not completed18
Withdrew: Death1
Withdrew: Never dosed with exa-cel17

Outcome measures

PrimaryPercentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel Infusion

A VOC is a condition of SCD characterized by vaso-occlusion presenting as recurrent pain episodes. The percentage of participants who remain VOC free after achieving VF12 were data reported in the outcome measure.

Time frame:
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Reported as:
Number · Percentage of participants
Percentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel Infusion
Percentage of participantsExa-cel (Exagamglogene Autotemcel)
Percentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel Infusion91.3 (79.2 to 97.6)
PrimaryPercentage of Participants Who Achieve Neutrophil Engraftment

Neutrophil engraftment is defined as the first day of 3 consecutive measurements of absolute neutrophil count (ANC)≥500/μL on 3 different days, within 42 days after exa-cel infusion without the use of unmodified CD34+ cells after reaching the nadir, defined as ANC \<500/µL.

Time frame:
Up to 24 months post exa-cel infusion.
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieve Neutrophil Engraftment
Percentage of ParticipantsExa-cel (Exagamglogene Autotemcel)
Percentage of Participants Who Achieve Neutrophil Engraftment100
PrimaryTime to Neutrophil Engraftment for Participants Who Achieve Neutrophil Engraftment

Neutrophil engraftment is defined as the first day of 3 consecutive measurements of absolute neutrophil count (ANC)≥500/μL on 3 different days, without use of the unmodified CD34+ cells after reaching the nadir, defined as ANC\<500/μL. Time to neutrophil engraftment was calculated by the neutrophil engraftment date subtract exa-cel infusion date +1.

Time frame:
Up to 24 months post exa-cel infusion.
Reported as:
Median · Days
Time to Neutrophil Engraftment for Participants Who Achieve Neutrophil Engraftment
DaysExa-cel (Exagamglogene Autotemcel)
Time to Neutrophil Engraftment for Participants Who Achieve Neutrophil Engraftment27.0 (15 to 40)
PrimaryTime to Platelet Engraftment for Participants Who Achieve Platelet Engraftment

Platelet engraftment is defined as the first day of 3 consecutive measurements of unsupported (no platelet transfusions for the last 7 days) platelet ≥50,000/μL on 3 different days after Exa-cel infusion. For participants discharged early day 7 after the last platelet transfusion will be the day of platelet engraftment, as long as 3 subsequent and consecutive unsupported measurements on 3 different days are \>50,000/μL. For participants who have been discharged prior to platelet engraftment, it is recommended to collect blood every 2 to 3 days to obtain an accurate assessment of platelet engraftment. Time to platelet engraftment was defined as first of 3 consecutive measurements on 3 different days with platelet ≥50 × 109/L without a platelet transfusion for 7 consecutive days.

Time frame:
From Exa-cel infusion up to 2 years after exa-cel infusion
Reported as:
Median · Days
Time to Platelet Engraftment for Participants Who Achieve Platelet Engraftment
DaysExa-cel (Exagamglogene Autotemcel)
Time to Platelet Engraftment for Participants Who Achieve Platelet Engraftment34.5 (23 to 126)
PrimarySafety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
From receiving exa-cel infusion up to 2 years
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsExa-cel (Exagamglogene Autotemcel)
Participants with TEAEs46
Participants with SAEs22
PrimaryTransplant-related Mortality (TRM) Within 100 Days After Exa-cel Infusion

The transplant-related mortality is defined as death related to Busulfan and/or exa-cel infusion. The number and proportion of TRM participants who have died within 100 days, or with at least 100 days post exa-cel infusion.

Time frame:
Within 100 days after exa-cel infusion
Reported as:
Count of participants · Participants
Transplant-related Mortality (TRM) Within 100 Days After Exa-cel Infusion
ParticipantsExa-cel (Exagamglogene Autotemcel)
Transplant-related Mortality (TRM) Within 100 Days After Exa-cel Infusion0
PrimaryTransplant-related Mortality Within 12 Months Post Exa-cel Infusion

The transplant-related mortality is defined as death related to Busulfan and/or exa-cel infusion. The number and proportion of TRM within 12 months will be summarized for participants who have died within 12 months, or with at least 12 months post exa-cel infusion.

Time frame:
Within 12 months post exa-cel infusion
Reported as:
Count of participants · Participants
Transplant-related Mortality Within 12 Months Post Exa-cel Infusion
ParticipantsExa-cel (Exagamglogene Autotemcel)
Transplant-related Mortality Within 12 Months Post Exa-cel Infusion1
PrimaryAll-cause Mortality

All-cause mortality from exa-cel infusion up to 2 years

Time frame:
From exa-cel infusion up to 2 years
Reported as:
Count of participants · Participants
All-cause Mortality
ParticipantsExa-cel (Exagamglogene Autotemcel)
All-cause Mortality1
SecondaryPercentage of Participants Free From Inpatient Hospitalization for Severe VOCs Sustained for at Least 12 Months (HF12)

The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion.

Time frame:
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Reported as:
Number · Percentage of participants
Percentage of Participants Free From Inpatient Hospitalization for Severe VOCs Sustained for at Least 12 Months (HF12)
Percentage of participantsExa-cel (Exagamglogene Autotemcel)
Percentage of Participants Free From Inpatient Hospitalization for Severe VOCs Sustained for at Least 12 Months (HF12)97.8 (88.5 to 99.9)
SecondaryRelative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion

The VF12 defines absence of any severe vaso-occlusive crises (VOCs) for at least 12 consecutive months after exa-cel infusion. Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs were included in the analysis. Relative reduction from baseline was calculated as 100 % × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years.

Time frame:
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Reported as:
Median · Percent Reduction
Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Percent ReductionExa-cel (Exagamglogene Autotemcel)
Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion65.5 (-162.5 to 76.9)
SecondaryPercentage of Participants With at Least 90% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion

Percentage of participants with at least 90% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.

Time frame:
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 90% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Percentage of participantsExa-cel (Exagamglogene Autotemcel)
Percentage of Participants With at Least 90% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion0
SecondaryPercentage of Participants With at Least 80% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion

Percentage of participants with at least 80% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.

Time frame:
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least 80% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Percentage of ParticipantsExa-cel (Exagamglogene Autotemcel)
Percentage of Participants With at Least 80% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion0
SecondaryPercentage of Participants With at Least 75% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion

Percentage of participants with at least 75% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.

Time frame:
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least 75% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Percentage of ParticipantsExa-cel (Exagamglogene Autotemcel)
Percentage of Participants With at Least 75% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion25.0
SecondaryPercentage of Participants With at Least 50% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion

Percentage of participants with at least 50% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.

Time frame:
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least 50% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Percentage of ParticipantsExa-cel (Exagamglogene Autotemcel)
Percentage of Participants With at Least 50% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion75.0
SecondaryDuration of Severe VOC Free in Participant Who Have Achieved VF12

The VF12 means the absence of any severe VOC for at least 12 consecutive months after exa-cel infusion. The evaluation of the severe VOC free duration in participants who achieved VF12 started 60 days after the last RBC transfusion for post transplant support or SCD management.

Time frame:
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Reported as:
Median · Months
Duration of Severe VOC Free in Participant Who Have Achieved VF12
MonthsExa-cel (Exagamglogene Autotemcel)
Duration of Severe VOC Free in Participant Who Have Achieved VF1221.4 (12.6 to 23.3)
SecondaryRelative Reduction From Baseline in Annualized Rate of Inpatient Hospitalizations for Severe VOCs Up to 24 Months After Exa-cel Infusion

The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion. Relative reduction from baseline is calculated as 100% × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years. Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs are included in the analysis.

Time frame:
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Reported as:
Mean · Percent Reduction
Relative Reduction From Baseline in Annualized Rate of Inpatient Hospitalizations for Severe VOCs Up to 24 Months After Exa-cel Infusion
Percent ReductionExa-cel (Exagamglogene Autotemcel)
Relative Reduction From Baseline in Annualized Rate of Inpatient Hospitalizations for Severe VOCs Up to 24 Months After Exa-cel Infusion49.7
SecondaryRelative Reduction From Baseline in Annualized Duration of Hospitalization for Severe VOCs Who Did Not Achieve HF12 Up to 24 Months After Exa-cel Infusion

The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion. Relative reduction from baseline is calculated as 100% × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years. Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs are included in the analysis.

Time frame:
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Reported as:
Mean · Percent Reduction
Relative Reduction From Baseline in Annualized Duration of Hospitalization for Severe VOCs Who Did Not Achieve HF12 Up to 24 Months After Exa-cel Infusion
Percent ReductionExa-cel (Exagamglogene Autotemcel)
Relative Reduction From Baseline in Annualized Duration of Hospitalization for Severe VOCs Who Did Not Achieve HF12 Up to 24 Months After Exa-cel Infusion61.7
SecondaryPercentage of Participants With Sustained Fetal Hemoglobin (HbF) Greater Than or Equal to (≥) 20% for at Least 3 Months

The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.

Time frame:
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Reported as:
Number · Percentage of Participants
Percentage of Participants With Sustained Fetal Hemoglobin (HbF) Greater Than or Equal to (≥) 20% for at Least 3 Months
Percentage of ParticipantsExa-cel (Exagamglogene Autotemcel)
Percentage of Participants With Sustained Fetal Hemoglobin (HbF) Greater Than or Equal to (≥) 20% for at Least 3 Months97.8 (88.5 to 99.9)
SecondaryPercentage of Participants With Sustained HbF ≥ 20% for at Least 6 Months

The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.

Time frame:
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Reported as:
Number · Percentage of Participants
Percentage of Participants With Sustained HbF ≥ 20% for at Least 6 Months
Percentage of ParticipantsExa-cel (Exagamglogene Autotemcel)
Percentage of Participants With Sustained HbF ≥ 20% for at Least 6 Months97.8 (88.5 to 99.9)
SecondaryPercentage of Participants With Sustained HbF ≥20% for at Least 12 Months

The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.

Time frame:
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Reported as:
Number · Percentage of Participants
Percentage of Participants With Sustained HbF ≥20% for at Least 12 Months
Percentage of ParticipantsExa-cel (Exagamglogene Autotemcel)
Percentage of Participants With Sustained HbF ≥20% for at Least 12 Months97.8 (88.5 to 99.9)
SecondaryNumber of Annualized Red Blood Cells (RBC) Units Transfused After Exa-cel Infusion

The evaluation of the number of annualized RBC units transfused after exa-cel infusion started 12 months after exa-cel infusion.

Time frame:
2 years after exa-cel infusion
Reported as:
Mean · RBC Units per year
Number of Annualized Red Blood Cells (RBC) Units Transfused After Exa-cel Infusion
RBC Units per yearExa-cel (Exagamglogene Autotemcel)
Number of Annualized Red Blood Cells (RBC) Units Transfused After Exa-cel Infusion0 ± 0.0
SecondaryParticipants With Relative Reduction From Baseline in Number of Annualized Units of Red Blood Cells Transfused

Relative reduction from baseline = 100% × (Baseline value - post baseline value)/Baseline value. The evaluation of the number of annualized RBC units transfused after exa-cel infusion started 12 months after exa-cel infusion.

Time frame:
2 years after exa-cel infusion
Reported as:
Mean · Percent reduction in RBC Units
Participants With Relative Reduction From Baseline in Number of Annualized Units of Red Blood Cells Transfused
Percent reduction in RBC UnitsExa-cel (Exagamglogene Autotemcel)
Participants With Relative Reduction From Baseline in Number of Annualized Units of Red Blood Cells Transfused100 ± 0.0
SecondaryTotal Fetal Hemoglobin (HbF) Concentration Over Time
Time frame:
2 years after exa-cel infusion
Reported as:
Mean · grams per deciliter (g/dL)
Total Fetal Hemoglobin (HbF) Concentration Over Time
grams per deciliter (g/dL)Exa-cel (Exagamglogene Autotemcel)
Total Fetal Hemoglobin (HbF) Concentration Over Time5.7 ± 1.5
SecondaryTotal Hemoglobin (Hb) Concentration Over Time
Time frame:
2 years after exa-cel infusion
Reported as:
Mean · g/dL
Total Hemoglobin (Hb) Concentration Over Time
g/dLExa-cel (Exagamglogene Autotemcel)
Total Hemoglobin (Hb) Concentration Over Time13.2 ± 1.8
SecondaryChange From Baseline in Reticulocyte Count Over Time
Time frame:
2 years after exa-cel infusion
Reported as:
Mean · 10^9 cells/liter
Change From Baseline in Reticulocyte Count Over Time
10^9 cells/literExa-cel (Exagamglogene Autotemcel)
Change From Baseline in Reticulocyte Count Over Time152.81 ± 71.80
SecondaryChange From Baseline in Indirect Bilirubin Over Time
Time frame:
2 years after exa-cel infusion
Reported as:
Mean · micromoles per liter (µmol/L)
Change From Baseline in Indirect Bilirubin Over Time
micromoles per liter (µmol/L)Exa-cel (Exagamglogene Autotemcel)
Change From Baseline in Indirect Bilirubin Over Time18.7 ± 15.6
SecondaryPercentage of Participants With Detectable Haptoglobin Over Time
Time frame:
2 years after exa-cel infusion
Reported as:
Number · Percentage of Participants
Percentage of Participants With Detectable Haptoglobin Over Time
Percentage of ParticipantsExa-cel (Exagamglogene Autotemcel)
Percentage of Participants With Detectable Haptoglobin Over Time100
SecondaryPercentage of Participants With Lactate Dehydrogenase (LDH) Level <300 Units Per Liter (U/L) Over Time
Time frame:
2 years after exa-cel infusion
Reported as:
Number · Percentage of Participants
Percentage of Participants With Lactate Dehydrogenase (LDH) Level <300 Units Per Liter (U/L) Over Time
Percentage of ParticipantsExa-cel (Exagamglogene Autotemcel)
Percentage of Participants With Lactate Dehydrogenase (LDH) Level <300 Units Per Liter (U/L) Over Time79.1
SecondaryPercentage of Alleles With Intended Genetic Modification Present in Peripheral Blood Leukocytes Over Time
Time frame:
2 years after exa-cel infusion
Reported as:
Median · Percentage
Percentage of Alleles With Intended Genetic Modification Present in Peripheral Blood Leukocytes Over Time
PercentageExa-cel (Exagamglogene Autotemcel)
Percentage of Alleles With Intended Genetic Modification Present in Peripheral Blood Leukocytes Over Time76.42 (52.29 to 88.97)
SecondaryPercentage of Alleles With Intended Genetic Modification Present in CD34+ Cells of Bone Marrow Over Time
Time frame:
2 years after exa-cel infusion
Reported as:
Median · Percentage
Percentage of Alleles With Intended Genetic Modification Present in CD34+ Cells of Bone Marrow Over Time
PercentageExa-cel (Exagamglogene Autotemcel)
Percentage of Alleles With Intended Genetic Modification Present in CD34+ Cells of Bone Marrow Over Time87.34 (49.44 to 95.98)
SecondaryChange in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥12 and <18 Years of Age

The 11-point pain numerical rating scale (NRS) is used to measures pain intensity on a 1-dimensional score ranging from 0 (no pain) to 10 (worst possible pain).

Time frame:
2 years after exa-cel infusion
Reported as:
Mean · score on a scale
Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥12 and <18 Years of Age
score on a scaleExa-cel (Exagamglogene Autotemcel)
Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥12 and <18 Years of Age-0.8 ± 0.6
SecondaryChange in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥18 and ≤35 Years of Age

The 11 point pain numerical rating scale (NRS) is used to measures pain intensity on a 1 dimensional score ranging from 0 (no pain) to 10 (worst possible pain).

Time frame:
2 years after exa-cel infusion
Reported as:
Mean · score on a scale
Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥18 and ≤35 Years of Age
score on a scaleExa-cel (Exagamglogene Autotemcel)
Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥18 and ≤35 Years of Age-1.7 ± 2.5
SecondaryChange in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-Y)Visual Analogue Scale (VAS) for Participants ≥12 and <18 Years of Age

The EQ-5D VAS is a version of the EQ-5D designed for children and adolescents S). The EQ VAS records the subject's self-rated health on a 100-point VAS scale that ranged from 0 (worst imaginable health) to 100 (best imaginable health) points.

Time frame:
2 years after exa-cel infusion
Reported as:
Mean · score on a scale
Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-Y)Visual Analogue Scale (VAS) for Participants ≥12 and <18 Years of Age
score on a scaleExa-cel (Exagamglogene Autotemcel)
Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-Y)Visual Analogue Scale (VAS) for Participants ≥12 and <18 Years of Age10.6 ± 22.9
SecondaryChange in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-5L) for Participants ≥18 and ≤35 Years of Age

The EQ-5D VAS is a version of the EQ-5D designed for children and adolescents S). The EQ VAS records the subject's self-rated health on a 100-point VAS scale that ranged from 0 (worst imaginable health) to 100 (best imaginable health) points.

Time frame:
2 years after exa-cel infusion
Reported as:
Mean · score on a scale
Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-5L) for Participants ≥18 and ≤35 Years of Age
score on a scaleExa-cel (Exagamglogene Autotemcel)
Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-5L) for Participants ≥18 and ≤35 Years of Age18.7 ± 22.1
SecondaryChange in PRO Over Time Assessed Using Functional Assessment of Cancer Therapy-bone Marrow Transplant (FACT-BMT) Score for Participants ≥18 and ≤35 Years of Age

The Functional Assessment of Cancer Therapy-Bone Marrow Transplant scale (FACT-BMT) is a quality of life instrument that assesses the effects of bone marrow transplantation (BMT) on a patient's physical, social/family, emotional, and functional well-being while taking into consideration BMT-specific concerns. The assessment has different questions, each scored on a Likert scale from 0-4. The overall score is computed by adding scores of the questions and falls in the range 0-148, with higher scores indicating higher levels of overall well-being.

Time frame:
2 years after exa-cel infusion
Reported as:
Mean · score on a scale
Change in PRO Over Time Assessed Using Functional Assessment of Cancer Therapy-bone Marrow Transplant (FACT-BMT) Score for Participants ≥18 and ≤35 Years of Age
score on a scaleExa-cel (Exagamglogene Autotemcel)
Change in PRO Over Time Assessed Using Functional Assessment of Cancer Therapy-bone Marrow Transplant (FACT-BMT) Score for Participants ≥18 and ≤35 Years of Age19.4 ± 22.1
SecondaryChange in PRO Over Time Assessed Using Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Score on Different Domains for Participants ≥18 and ≤35 Years of Age

ASCQ-Me is a disease-specific HRQoL questionnaire for adults with sickle cell disease that assesses Emotional Impact, Pain Impact, Social Functioning Impact, Stiffness Impact, Sleep Impact, Pain Episode Frequency, and Pain Episode Severity. Domain scores are reported as T-scores standardized to a reference population where mean = 50, and SD = 10. A change of approximately 5 points (1/2 SD) is considered clinically meaningful. An increase of 5 points indicates improvement for the impact domains, whereas a decrease of 5 points indicates improvement for the Pain Episode Frequency and Pain Episode Severity domains. For impact domain items higher score indicates better HRQoL and lower disease burden. For Pain items lower score indicates a better outcome. Scores are interpreted relative to the reference population mean of 50, taking into account the direction of scoring for each domain.

Time frame:
2 years after exa-cel infusion
Reported as:
Mean · T-score
Change in PRO Over Time Assessed Using Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Score on Different Domains for Participants ≥18 and ≤35 Years of Age
T-scoreExa-cel (Exagamglogene Autotemcel)
Emotional Impact Score9.1 ± 9.2
Pain Impact Score6.9 ± 8.8
Social Functioning Score13.0 ± 12.9
Stiffness Impact Score5.3 ± 8.7
Sleep Impact Score5.2 ± 9.2
Pain Episode Frequency Score-21.1 ± 9.7
Pain Episode Severity Score-1.4 ± 12.6
SecondaryChange in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age

PedsQL scores were used to assess quality of life of participants. It is a standardized, generic instrument for measuring health related quality of life (HRQoL) in children and adolescents. It includes different domains (Psychosocial health, physical functioning, emotional functioning, social functioning, and school functioning). When completing the PedsQL questionnaires, respondents were asked to provide a response on a 5-point scale ranging from 0 (never a problem) to 4 (almost always a problem). Responses were then transformed to a 0 to 100 score, with higher scores reflecting better quality of life.

Time frame:
2 years after Exa-cel infusion
Reported as:
Mean · score on a scale
Change in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age
score on a scaleExa-cel (Exagamglogene Autotemcel)
Psychosocial Health Score25.0 ± 15.7
Physical Functioning Score29.7 ± 24.3
Emotional Functioning Score20.5 ± 16.9
Social Functioning Score18.5 ± 18.1
School Functioning Score36.0 ± 26.3
SecondaryChange in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module (SCD) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age

The PedsQL Sickle Cell Disease Module (PedsQL SCD) is a disease-specific module of the PedsQL. The tool measures self-reported health-related quality of life in participants with SCD across 9 domains: pain and hurt, pain impact, pain management (mgmt), worry I, worry II, emotions, treatment, communication I, and communication II. When completing the PedsQL SCD Module questionnaires, respondents were asked to provide a response on a 5-point scale ranging from 0 (never a problem) to 4 (almost always a problem). Responses were then transformed to a 0 to 100 score, with higher scores reflecting better quality of life.

Time frame:
2 years after exa-cel infusion
Reported as:
Mean · score on a scale
Change in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module (SCD) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age
score on a scaleExa-cel (Exagamglogene Autotemcel)
Pain and Hurt Score29.7 ± 19.3
Pain Impact Score48.5 ± 29.4
Pain Mgmt Score27.5 ± 32.2
Worry I Score29.0 ± 15.1
Worry II Score18.8 ± 17.9
Emotions Score31.3 ± 29.0
Treatment Score23.9 ± 15.4
Communication I Score16.7 ± 19.6
Communication II Score20.8 ± 48.0

Adverse events

Collected over From Exa-cel infusion up to 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Exa-cel (Exagamglogene Autotemcel)1/46 (2.2%)22/46 (47.8%)46/46 (100%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventExa-cel (Exagamglogene Autotemcel)
PyrexiaGeneral disorders4/46
CholelithiasisHepatobiliary disorders4/46
PneumoniaInfections and infestations4/46
Sickle cell anaemia with crisisBlood and lymphatic system disorders3/46
Abdominal painGastrointestinal disorders3/46
ConstipationGastrointestinal disorders3/46
Abdominal pain upperGastrointestinal disorders2/46
DiarrhoeaGastrointestinal disorders2/46
Non-cardiac chest painGeneral disorders2/46
PainGeneral disorders2/46
Most frequent other events
Showing 10 of 112
Most frequent other events
EventExa-cel (Exagamglogene Autotemcel)
NauseaGastrointestinal disorders32/46
StomatitisGastrointestinal disorders29/46
VomitingGastrointestinal disorders27/46
Febrile neutropeniaBlood and lymphatic system disorders25/46
HeadacheNervous system disorders25/46
Abdominal painGastrointestinal disorders24/46
PruritusSkin and subcutaneous tissue disorders23/46
ConstipationGastrointestinal disorders21/46
DiarrhoeaGastrointestinal disorders21/46
Platelet count decreasedInvestigations21/46

Baseline characteristics

Baseline data was analyzed based on the Full Analysis Set (FAS), defined as all participants who received the exa-cel infusion.

Age, Continuous
Age, Continuous(Years)Exa-cel (Exagamglogene Autotemcel)
Mean21.4 ± 6.0
Sex: Female, Male
Sex: Female, Male(Participants)Exa-cel (Exagamglogene Autotemcel)
Female21
Male25
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Exa-cel (Exagamglogene Autotemcel)
Hispanic or Latino2
Not Hispanic or Latino43
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Exa-cel (Exagamglogene Autotemcel)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American39
White4
More than one race0
Unknown or Not Reported3
08

Study locations

17 sites
  • Lucile Packard Children's Hospital of Stanford University
    Palo Alto, California 94304, United States
  • Ann & Robert Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Illinois at Chicago Hospitals and Health Systems
    Chicago, Illinois 60612, United States
  • Columbia University Medical Center (21+ years)
    New York, New York 10032, United States
  • Columbia University Medical Center (≤21 years)
    New York, New York 10032, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers
    Nashville, Tennessee 37203, United States
  • Methodist Children's Hospital/Texas Transplant Institute
    San Antonio, Texas 78229, United States
  • Hopital Universitaire des Enfants Reine Fabiola (HUDERF)
    Brussels, Belgium
  • The Hospital for Sick Children
    Toronto, Canada
  • Hopital Necker Enfants Malades
    Paris, France
  • University Hospital Duesseldorf
    Düsseldorf, Germany
  • Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine, Paediatric Haemotology, Oncology and Stem Cell Transplantation
    Regensburg, Germany
  • Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS
    Rome, Italy
  • Imperial College Healthcare NHS Trust, Hammersmith Hospital
    London, United Kingdom
  • Royal London and St Bartholomew's Hospital, Pathology and Pharmacy Building
    London, United Kingdom
09

References and documents

Publications

  • Sharma A, Locatelli F, Bhatia M, Molinari L, Mapara MY, Liem RI, Dedeken L, Wall D, Eckrich MJ, Kuo KHM, Smith W, Imren S, Kohli P, Li N, Liu T, Rubin J, Hobbs W, Grupp SA, Frangoul H. Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel. Blood Adv. 2025 Dec 23;9(24):6481-6490. doi: 10.1182/bloodadvances.2025016701. PubMed 40857358 ↗
  • Ligon JA, Cupit-Link MC, Yu C, Levine J, Foley T, Rotz S, Sharma A, Gomez-Lobo V, Shah NN. Pediatric Cancer Immunotherapy and Potential for Impact on Fertility: A Need for Evidence-Based Guidance. Transplant Cell Ther. 2024 Aug;30(8):737-749. doi: 10.1016/j.jtct.2024.06.006. Epub 2024 Jun 10. PubMed 38866240 ↗
  • Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, Wall D, Liem RI, Telfer P, Shah AJ, Cavazzana M, Corbacioglu S, Rondelli D, Meisel R, Dedeken L, Lobitz S, de Montalembert M, Steinberg MH, Walters MC, Eckrich MJ, Imren S, Bower L, Simard C, Zhou W, Xuan F, Morrow PK, Hobbs WE, Grupp SA; CLIMB SCD-121 Study Group. Exagamglogene Autotemcel for Severe Sickle Cell Disease. N Engl J Med. 2024 May 9;390(18):1649-1662. doi: 10.1056/NEJMoa2309676. Epub 2024 Apr 24. PubMed 38661449 ↗
  • Sharma A, Young A, Carroll Y, Darji H, Li Y, Mandrell BN, Nelson MN, Owens CL, Irvine M, Caples M, Jerkins LP, Unguru Y, Hankins JS, Johnson LM. Gene therapy in sickle cell disease: Attitudes and informational needs of patients and caregivers. Pediatr Blood Cancer. 2023 Jun;70(6):e30319. doi: 10.1002/pbc.30319. Epub 2023 Mar 28. PubMed 36975201 ↗
  • Persaud Y, Mandrell BN, Sharma A, Carroll Y, Irvine M, Olufadi Y, Kang G, Hijano DR, Rai P, Hankins JS, Johnson LM. Attitudes toward COVID-19 vaccine among pediatric patients with sickle cell disease and their caregivers. Pediatr Blood Cancer. 2023 May;70(5):e30274. doi: 10.1002/pbc.30274. Epub 2023 Mar 1. PubMed 36860093 ↗
  • Bhoopalan SV, Yen JS, Levine RM, Sharma A. Editing human hematopoietic stem cells: advances and challenges. Cytotherapy. 2023 Mar;25(3):261-269. doi: 10.1016/j.jcyt.2022.08.003. Epub 2022 Sep 17. PubMed 36123234 ↗
  • Brusson M, Miccio A. Genome editing approaches to beta-hemoglobinopathies. Prog Mol Biol Transl Sci. 2021;182:153-183. doi: 10.1016/bs.pmbts.2021.01.025. Epub 2021 Mar 1. PubMed 34175041 ↗
  • Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R, Ho TW, Kattamis A, Kernytsky A, Lekstrom-Himes J, Li AM, Locatelli F, Mapara MY, de Montalembert M, Rondelli D, Sharma A, Sheth S, Soni S, Steinberg MH, Wall D, Yen A, Corbacioglu S. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5. PubMed 33283989 ↗
  • Modarai SR, Kanda S, Bloh K, Opdenaker LM, Kmiec EB. Precise and error-prone CRISPR-directed gene editing activity in human CD34+ cells varies widely among patient samples. Gene Ther. 2021 Feb;28(1-2):105-113. doi: 10.1038/s41434-020-00192-z. Epub 2020 Sep 1. PubMed 32873924 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Jul 2025, 79 months.

Results were first posted in Sep 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2018
First posted
Nov 19, 2018
StartActual
Nov 27, 2018
Primary completionActual
Jul 7, 2025
CompletionActual
Jul 7, 2025
Results first posted
Sep 16, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03745287
Collaborators
CRISPR Therapeutics
Responsible party
Sponsor
First posted
Nov 19, 2018
Start date
Nov 27, 2018
Primary completion
Jul 7, 2025
Completion
Jul 7, 2025
Results posted
Sep 16, 2026
Last update
Sep 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Exagamglogene autotemcel

Start the discussion